Clinical trials: Nonproliferative Diabetic Retinopathy
Diabetic Retinopathy
A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
The purpose of this study is to determine the safety and efficacy of Vitreosolve in diabetic retinopathy patients.
- Trial name
- NCT00664183
- Testing
- Vitreosolve
- Where
- 17 sites in United States, India
- Volunteers
- 400 people
- Sponsor
- Vitreoretinal Technologies, Inc.
Non-proliferative Diabetic Retinopathy (NPDR)
Efficacy and Safety of Ginkgo Biloba Extract EGb761® in Patients With Diabetic Retinopathy
This study is a single-center, open-label, parallel-controlled trial, scheduled to commence in October 2025 at the outpatient and inpatient departments of Shanghai General Hospital.
- Trial name
- NCT07236645
- Testing
- Ginaton (ginkgo biloba extract tablet), standard treatment
- Volunteers
- 200 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Diabetic Retinopathy
Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy
This 24 month randomized research study will evaluate whether doxycycline can slow the deterioration or improve retinal function among patients with mild to moderate non-proliferative diabetic retinopathy.
- Trial name
- POC2 (NCT00917553)
- Testing
- doxycycline monohydrate
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Thomas Gardner
Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema
Ultra-wide field fluorescein angiography can detect the response of anti VGEF therapy such as Avastin on retinal ischemia in the setting of diabetic macular edema.
- Conditions
- Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT02096874
- Testing
- Bevacizumab
- Where
- Saudi Arabia
- Volunteers
- 50 people
- Sponsor
- King Khaled Eye Specialist Hospital
Diabetic Retinopathy
Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
This multicenter, open-label extension study will evaluate the long-term tolerability and safety for patients completing study CSMS995 0802.
- Trial name
- NCT00248157
- Testing
- Octreotide acetate in microspheres
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Non-proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
- Trial name
- GLOW (NCT05066230)
- Testing
- KSI-301
- Where
- 61 sites in United States, Czechia and 5 more
- Volunteers
- 253 people
- Sponsor
- Kodiak Sciences Inc
Neovascular Age-related Macular Edema, Diabetic Macular Edema
Anti-VEGF in Real-world
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of…
- Conditions
- Neovascular Age-related Macular Edema, Diabetic Macular Edema, Choroidal Neovascular Membrane, Non-proliferative Diabetic Retinopathy
- Trial name
- NCT05222633
- Testing
- Ranibizumab, Aflibercept, Conbercept
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Wenbin Wei
Diabetic Macular Edema, Non-proliferative Diabetic Retinopathy
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
The purpose of this study is to test the efficacy of an 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular leakage and visual acuity for patients with recalcitrant diabetic macular edema.
- Conditions
- Diabetic Macular Edema, Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
- Trial name
- NCT01571232
- Testing
- dexamethasone intravitreal implant, intravitreal bevacizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Retina Macula Institute
Diabetic Retinopathy, Non Proliferative Diabetic Retinopathy
Randomized, Controlled Study to Investigate the 12-month Efficacy and Safety of Resveratrol Vitamin Supplements in Patients With Non-proliferative Diabetic Retinopathy Without Center Involved Diabetic Macular Edema (REVOLUTION Study)
This randomized, controlled study aims to investigate the efficacy and safety of resveratrol-containing vitamin supplements in patients with non-proliferative diabetic retinopathy (NPDR) without center-involved diabetic macular…
- Conditions
- Diabetic Retinopathy, Non Proliferative Diabetic Retinopathy, Prospective Study
- Trial name
- REVOLUTION (NCT07868458)
- Testing
- Resveratrol-Containing Vitamin Supplement
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- University of Athens
Diabetic Retinopathy
A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.
The main objective is to evaluate ocular and systemic safety and tolerability of BI 1467335 as well as whether BI 1467335 monotherapy has a potential to improve retinal lesions in patients with moderately severe Non-proliferative…
- Trial name
- ROBIN (NCT03238963)
- Testing
- BI 1467335
- Where
- 35 sites in United States, Austria and 6 more
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Type (NPDR).
- Trial name
- NCT06770933
- Testing
- VX-01
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 100 people
- Sponsor
- Vantage Biosciences Ltd
Severe Non-proliferative Diabetic Retinopathy
Safety and Effectiveness Study of 532nm Laser Subthreshold Panretinal Photocoagulation for Severe NPDR
This randomized, parallel controlled, clinical-trial aims to evaluate the therapeutic efficacy of 532nm laser partially subthreshold panretinal photocoagulation with PASCAL endpoint management function for severe…
- Trial name
- S-PRP (NCT01759121)
- Testing
- T-PRP, S-PRP
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Non-Proliferative Diabetic Retinopathy, Retinal Vein Occlusion
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion
The goal of this clinical trial is to learn about the safety of the investigational medicinal product ANXV. It will also learn about how ANXV works to treat non-proliferative diabetic retinopathy and retinal vein occlusion in…
- Trial name
- NEXUS (NCT07259928)
- Testing
- ANXV
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Annexin Pharmaceuticals AB
Non Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment
Laser photocoagulation has become the treatment of choice in PDR. Laser photocoagulation has become the treatment of choice in PDR.
- Trial name
- NCT00563043
- Testing
- PASCAL laser treatment
- Where
- Mexico
- Volunteers
- 8 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Mild Non-proliferative Diabetic Retinopathy, Cataract Diabetic
Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy
Diabetic retinopathy has been found progress in 20-70% diabetic patient after cataract phacoemulsification surgery. Intravitreal injection of anti-VEGF Ranibizumab is an important treatment for diabetic retinopathy including…
- Conditions
- Mild Non-proliferative Diabetic Retinopathy, Cataract Diabetic, Diabetic Retinopathy
- Trial name
- NCT05386160
- Testing
- Ranibizumab Injection [Lucentis], Phacoemulsification
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Ruijin Hospital
Diabetic Retinopathy
Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy.
Diabetic retinopathy (DR) is a common complication of diabetes mellitus that leads to loss of vision and blindness among working age adults.
- Trial name
- NCT04552600
- Testing
- Nuvastatic
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Natureceuticals Sdn Bhd
NPDR - Non Proliferative Diabetic Retinopathy, Diabetes Mellitus, Type 2
Characterization of Retinal Disease Progression in Eyes With Non Proliferative Diabetic Retinopathy in Diabetes Type 2 Using Non-invasive Procedures (CHART)
To identify biomarkers, obtained using non-invasive procedures, that can predict disease progression and progression to sight-threatening stages of the disease and to characterize the retinal changes that occur in Non…
- Conditions
- NPDR - Non Proliferative Diabetic Retinopathy, Diabetes Mellitus, Type 2, Retinal Disease
- Trial name
- CHART (NCT04636307)
- Testing
- Biomarkers
- Where
- 5 sites in France, Italy and 1 more
- Volunteers
- 202 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG)
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
- Conditions
- Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
- Trial name
- (PENGUIN) (NCT07354477)
- Testing
- QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Qlaris Bio, Inc.
Diabetic Retinopathy, Sleep Apnea
CPAP Effect on the Progression of Diabetic Retinopathy in Patients With Sleep Apnea
Objectives: Main objective: To compare the percentage of patients with new microaneurysm or hard exudates after 12 months between the CPAP group and the control group.
- Trial name
- RetinAS (NCT02874313)
- Testing
- Continuous positive airway pressure, Pharmacological treatment, Conventional anti-diabetic diet recommendations
- Where
- Spain
- Volunteers
- 82 people
- Sponsor
- Hospital Universitario La Paz
Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy
Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy
The goal of this clinical trial is to evaluate whether remote ischemic conditioning (RIC) is a safe and effective treatment for non-proliferative diabetic retinopathy (NPDR) in adults aged 40-80 years with type 2 diabetes.
- Conditions
- Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy, Remote Ischemic Conditioning, Diabetes Mellitus, Type 2
- Trial name
- RIC-NPDR (NCT06713720)
- Testing
- Remote Ischemic Conditioning Device
- Where
- 2 sites in China
- Volunteers
- 68 people
- Sponsor
- Xuxiang Zhang, MD